From: Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience
Variable |
DA-EPOCH-R/MA (n, % ) |
DA-EPOCH-R (n, % ) |
R-HyperCVAD (n, % ) | P value |
---|---|---|---|---|
Age | 0.711 | |||
≤ 50 years | 9 (64.3) | 9 (50.0) | 10 (62.5) | |
50–60 years | 5 (35.7) | 9 (50.0) | 6 (37.5) | |
Laterality | 0.965 | |||
Right | 4 (28.6) | 7 (38.9) | 5 (31.3) | |
Left | 7 (50.0) | 8 (44.4) | 7 (43.8) | |
Bilateral | 3 (21.4) | 3 (16.7) | 4 (25.0) | |
Tumour size | 0.811 | |||
< 5 cm | 8 (57.1) | 11 (61.1) | 11 (68.8) | |
≥ 5 cm | 6 (42.9) | 7 (38.9) | 5 (31.3) | |
Cell of origin | 0.890 | |||
GCB | 11 (78.6) | 15 (83.3) | 14 (87.5) | |
Non-GCB | 3 (21.4) | 3 (16.7) | 2 (12.5) | |
Results of FISH | 0.745 | |||
MYC-BCL2 | 10 (71.4) | 15 (83.3) | 13 (81.3) | |
MYC-BCL6 | 4 (28.6) | 3 (16.7) | 3 (18.8) | |
C-MYC of IHC | 1.000 | |||
C-MYC (+) | 14 (100.0) | 18 (100.0) | 16 (100.0) | |
BCL2 of IHC | 0.521 | |||
BCL2 (+) | 13 (92.9) | 18 (100.0) | 15 (93.8) | |
BCL6 of IHC | 0.767 | |||
BCL6 (+) | 14 (100.0) | 16 (88.9) | 15 (93.8) | |
CD5 of IHC | 0.406 | |||
CD5 (+) | 5 (35.7) | 4 (22.2) | 7 (43.8) | |
CD10 of IHC | 0.661 | |||
CD10 (+) | 10 (71.4) | 10 (55.6) | 9 (56.3) | |
P53 of IHC | 0.926 | |||
P53 (+) | 9 (64.3) | 13 (72.2) | 11 (68.8) | |
Ki-67 of IHC | 0.668 | |||
Ki-67 ≥ 70 % | 12 (85.7) | 17 (94.4) | 15 (93.8) | |
Chromosomal abnormality | 0.700 | |||
Present | 3 (21.4) | 6 (33.3) | 3 (18.8) | |
Ann Arbor Staging | 0.832 | |||
IE | 4 (28.6) | 6 (33.3) | 3 (18.8) | |
IIE | 7 (50.0) | 7 (38.9) | 7 (43.8) | |
IV | 3 (21.4) | 5 (27.8) | 6 (37.5) | |
B symptoms | 0.652 | |||
Present | 10 (71.4) | 10 (55.6) | 10 (62.5) | |
LDH level | 0.544 | |||
Elevated | 5 (35.7) | 7 (38.9) | 9 (56.3) | |
Risk stratification | 0.665 | |||
L and L-I | 9 (64.3) | 9 (50.0) | 9 (56.3) | |
H and H-I | 5 (35.7) | 9 (50.0) | 7 (43.8) | |
ASCT | 0.811 | |||
Yes | 6 (42.9) | 7 (38.9) | 5 (31.3) |